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doi:10.1016/j.jprot.2011.06.031A B S T R A C TAvailable online 20 July 2011 The characterization of the normal urinary proteome is steadily progressing and represents
amajor interest in the assessment of clinical urinary biomarkers. To estimate quantitatively
the variability of the normal urinary proteome, urines of 20 healthy people were collected.
We first evaluated the impact of the sample conservation temperature on urine proteome
integrity. Keeping the urine sample at RT or at +4 °C until storage at −80 °C seems the best
way for long-term storage of samples for 2D-GE analysis. The quantitative variability of the
normal urinary proteome was estimated on the 20 urinesmapped by 2D-GE. The occurrence
of the 910 identified spots was analysed throughout the gels and represented in a virtual 2D
gel. Sixteen percent of the spots were found to occur in all samples and 23% occurred in at
least 90% of urines. About 13% of the protein spots were present only in 10% or less of the
samples, thus representing the most variable part of the normal urinary proteome. Twenty
proteins corresponding to a fraction of the fully conserved spots were identified by mass
spectrometry. In conclusion, a “public” urinary proteome, common to healthy individuals,
seems to coexist with a “private” urinary proteome, which is more specific to each
individual.
© 2011 Elsevier B.V. All rights reserved.Keywords:
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Variability1. Introduction
Although it is commonly believed that there is no significant
protein excretion in the urine of healthy individuals, evidence
for the presence of a highly diverse set of proteins is now
unambiguous. Since urine is formed by ultrafiltration of serum
through the kidney glomeruli, some amounts of many serum
proteins are present in the filtrate. Moreover, during its
passage through the filtration tubules, some proteins are
removed or degraded and others are added from the liningCNRS Bio-Rad, 1682 rue d
rs.fr (F. Molina).
ier B.V. All rights reserveepithelial cells to the fluid. At the end of the process, urine is a
rich and complex mixture of invaluable utility in clinical
proteomics [1,2]. Since the pioneering work of Anderson [3],
several studies have analysed the content of the human
urinary proteome by different techniques such as two
dimensional-gel electrophoresis (2D-GE), SELDI and mass
spectrometry (CE-MS and LC-MS/MS) [2,4–20]. More than
3000 proteins have been identified in the human normal
urinary proteome and collected in a database established from
19 published studies (DUP: Database of Urinary Proteins,e la Valsière, CS 61003, 34184 Montpellier Cedex 4, France. Tel.: +33
d.
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the same proteins in these 19 studies was very variable, some
proteins being reproducibly identified, some being unique to a
study. In most of these reports, pooled urines from several
individuals were used, possibly adding some inter-individual
variability to the natural complexity of the proteome, in
addition to variations arising from sample handling or storage.
Factors thatmight influence the composition of the urinary
proteome are gender, age, diet, time of collection, exercise, etc.
[12,17,21]. The extent of this variability has, however, rarely
been studied specifically and the few studies, which used a
2D-GE approach present conflicting results. Indeed, Laffite and
colleagues observed a strong conservation of five categories of
proteins in urine samples from 4males [22]. Conversely, Khan
and co-workers found significant changes when comparing
the proteomic profiles of urine samples from a single
individual collected at different times in a single day and
then once a week [17]. Oh and colleagues also reported
important variations in the 2D patterns of three subjects [12]
and Thongboonkerd and co-workers concluded that a consid-
erable degree of inter-individual variability exists [21]. It is
possible that the low number of individual samples studied
and the lack of rigorous estimation of the variability of each
spot might have contributed to these discrepancies. Recently,
Nagaraj and Mann measured the variability of the human
normal urinary proteome by LC-MS/MS in samples collected
on three consecutive days and found that the normal urinary
proteome was highly conserved [20].
For the identificationofurinary biomarkers of renal diseases,
it becomes important not only to rigorously list the components
of the urinary proteome, but also to understand towhich extent
the urinary proteome is variable. Here, we tried to estimate
quantitatively by 2D-GE approach, the portion of the urinary
proteome shared among twenty healthy individuals and to
analyse the variability of each protein spot in the 20 gels.
Moreover, since in clinical proteomic the conditions of sample
handlingmay significantlymodify the urinary proteome profile
of the studied individuals (in addition to inter-individual
variations), we also evaluated the impact of the temperature
at which samples were kept after collection and during storage
on urine proteome integrity.2. Materials and methods
2.1. Urine collection and storage
Second-morning urine samples from 20 random consenting
healthy individuals (10 males and 10 females, aged 22 to
59 years) were collected in sterile cups containing phosphatase
and protease inhibitors (PI), as recommended [23]. The donors
had no acute or chronic disease. Urinary sampleswere stored at
−80 °C until use. For assessing the impact of different storage
conditions, four biological samples (collected once and then
1month later) were used rapidly or after storage at −20 °C (for
2 weeks to 1 month) with or without PI. To evaluate the impact
of temperature just after urine collection, samples from two
normal individualswerecollected, kept at roomtemperature for
1 hand thenstoredat+4 °Cor roomtemperature for another 7 h
before freezing at −80 °C.2.2. Sample preparation
Urines were centrifuged at 4 °C at 11,000 g for 30 min and
supernatants dialysed against 18.2 MΩ·cmwater at 4 °C for 48 h.
Samples were then concentrated using 5000 Da cut-off centri-
fuge tubes (Millipore, Bedford,MA) at 4 °C to approximately 1/40
of the initial volume. Concentrated urines were lyophilised and
then solubilised in buffer containing 8 M urea, 2 M thiourea, 4%
w/v CHAPS, 65 mM DTE, 40mM Tris-base and protease in-
hibitors cocktails (Roche Diagnostics, Meylan, France) at room
temperature on a rotating wheel for 2 h. To determine the best
protein quantification assay, the Bradford method [24] and the
Lowry method (RCDC protein assay kit; Bio-Rad, Hercules, CA)
were compared by analysing seven normal urine samples three
times and by two different experimenters.
2.3. 2-D gel electrophoresis (2D-GE)
Precast IPG strips (18 cm) with a nonlinear immobilised pH 3–
10 gradient were rehydrated with 70 μg of protein sample in
8 M urea, 2 M thiourea, 4%w/v CHAPS, 65 mMDTE, 0.0025% v/v
bromophenol blue and 1% v/v IPG buffer (3−10) overnight [25].
Isoelectric focusing (IEF) was carried out on an Ettan™
IPGphor™ at 20 °C using a gradient mode to a total amount
of 50 kVh. During IEF, we tested the addition to the strip
extremities of paper soaked with water or DeStreak Rehydra-
tion Solution (GE Healthcare Life Sciences, Piscataway, NJ) or
DTE (20, 50 or 100mM). After the first dimension run, proteins
were reduced (65mM DTT in 6 M urea, 50 mM Tris–HCl, pH 8.8,
30% v/v glycerol, 2% w/v SDS, 0.001 v/v bromophenol blue) and
alkylated for 10 min in a similar buffer containing 135mM
iodoacetamide instead ofDTT. Then, proteinswere separated in
the second dimension on homemade 12% SDS-polyacrylamide
gels using an ISO-DALT electrophoresis unit at a constant
voltage of 120 V at 10 °C overnight. The analytical gels were
stained with silver nitrate and the preparative gels with
colloidal Coomassie blue G-250. In this last case, 200 μg of
protein were loaded per gel.
2.4. Image analysis
Gel imageswere digitalised at 300 dpi with an ImageScanner™
(GE Healthcare Life Sciences, Piscataway, NJ) and then
analysed using the Progenesis Samespot® software v3.0
(Nonlinear Dynamics, Durham, UK). Images were warped for
accurate alignment and spots were then automatically
detected. Progenesis Samespot® is based on the concept of
recursive gel matching, which means that each gel of a
matching set is recursively used as “reference gel” once during
thematching process. The quality of the automaticmatchwas
critically evaluated in each case, and if necessary, corrections
were done manually.
2.5. Data processing
Stringent criteria were applied to detect true protein spots in 2D
gels. For each protein spot detected by Progenesis Samespot®,
an intensity value was measured and then the background
noise (average value of 10 different areas of the gel without
apparent spot+four standard deviations) was subtracted. Thus,
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background subtraction. The variability of a given spot was
assessed by counting its occurrence in each of the 20 gels.
To assess the reproducibility of the 2D-GE technique, three
series of 2D-GE experimentswere performedwith four different
samples (repeated in duplicate in each series). For each sample
(593protein spots), thepercentagesof varianceswere calculated
from the mean coefficient of variation (CV), which is the
standard deviation divided by the mean of a measurement.
Technical, intra-individual and inter-individual coefficients of
variationswere calculated per gel andper spots. The correlation
between CV andmean intensity was computed with the JMP v8
software (Spearman correlation coefficient).
2.6. Data quality evaluation and statistics
All statistics anddatawere computedusing the JMPv8 software.
Comparisonof collection and storage conditionswasperformed
with the Student's t-test (p<0.05).
2.6.1. Dispersion tree
The dispersion tree method, as described in [26], was used.
Briefly, spot intensities in each gel were represented by an
expression vector of dimension n (n being the number of
spots). The Euclidian distance between vectors, which repre-
sents all experiments and their spots intensities, was calcu-
lated. The resulting distance matrix was used to perform a
clustering of all the experiments. The clustering and the
resulting unrooted “dispersion tree” graphical representation
were performed with the PHYLIP v3.6 package (http://
evolution.genetics.washington.edu/phylip.html).
2.6.2. Outlier detection using the Mahalanobis distance
The Mahalanobis distance depends on estimates of the mean,
standard deviation and correlation of the data. For each value,
the distance is denoted dM and is computed as:
dM xð Þ =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
x−μð ÞΤ∑−1 x−μð Þ
q
Using the Mahalanobis distance, we could measure the
distance of each gel, described by a multivariate vector x, to
the distribution of all other n gels, characterised by their mean
μ and covariance matrix Σ. The distance was plotted for each
gel and outlier gels could be identified by highlighting the
points with the largest distance values.
2.6.3. Principal component analysis (PCA)
PCA is a technique to take linear combinations of the original
variables such that the first principal component has maxi-
mum variation; the second principal component has the next
most variation subject to being orthogonal to the first and the
remaining components must all display these two features.
The ranking of components in decreasing order determines
the data variability. PCA is thus used to attribute the overall
data variability to a reduced set of variables, which are called
“principal components”. The first two principal components
are used tomap each gel in a 2D plot. With this approach, a gel
that deviates too much from the others can be considered as
an outlier.2.6.4. Pearson correlation matrix
The Pearson correlation coefficient measures the strength of
the linear relationship between two gels. For x and y gels, it is
denoted as r and computed as:
rxy =
∑
n
i=1
xi−xð Þ yi−yð Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
n
i=1
xi−xð Þ2 ∑
n
i=1
yi−yð Þ2
s
If there is an exact linear relationship between two gels, the
correlation is 1 or −1, depending on whether the variables are
positively or negatively related. If there is no linear relation-
ship, the correlation is close to zero. A matrix of correlation
coefficients is calculated and a colour map of the Pearson
correlations coefficients is plotted to show the groups of gels
that have similar correlations (on a scale from red (+1) to green
(−1)).
2.6.5. Hierarchical ascendant clustering analysis
HAC is a method of cluster analysis, based on a pairwise
distance matrix, which builds a hierarchy of clusters with
sequentially agglomerative and divisive approaches. We have
used this method to organise the map and to group the spots
according to the nearest level of intensity. For this analysis,
raw data were mean-centred and Pearson correlation matrix
and average linkage were chosen as parameters.
2.7. Virtual 2D gels
The Sili2DGel algorithm [27] was used for its capacity to
generate virtual gels from data derived from the Progenesis
Samespot® alignment.
2.8. Protein identification
Several fully conserved spots (occurring in different areas of
the gels) but presenting different intensities were excised from
preparative gels and washed successively with water, 25 mM
ammonium bicarbonate, acetonitrile/25 mM ammonium bi-
carbonate (1:1, v/v) and pure acetonitrile. A small number of
variable spots were also excised. Dried gels were rehydrated in
25 mM ammonium bicarbonate (pH 7.8) containing 0.1 μg
trypsin (Sequencing Grade Modified Trypsin, Promega,
Madison, USA) and incubated at 37 °C overnight. The resulting
peptides were extracted twice from the gel pieces with
acetonitrile/water (3:2, v/v) containing 0.1% trifluoroacetic
acid in an ultrasonic bath for 15 min. Supernatants were
pooled and the final volume was reduced to 10 μl under
vacuum. Trypsin-digested samples (0.8 μl) were mixed with
0.8 μl of matrix solution (α-cyano-4-hydroxycinnamic acid)
and spotted on the MALDI target.
MS andMS/MS analysiswere performed, in positive reflector
mode, using an UltraFlex II mass spectrometer (Bruker Dal-
tonics). All spectra were externally calibrated with a peptide
mix. Typically, 200 laser shots were summed to generate a
peptidemass fingerprint for each protein digest. MS andMS/MS
spectra annotations were performed manually and only peaks
witha signal tonoise ratiohigher than3were taken intoaccount
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the MASCOT software (Matrix Science, London, UK) and
searched against MSDB database (3,239,079 sequences) with
the following parameters: mammalian taxonomy, trypsin
digestion with one missed cleavage allowed, carbamidomethyl
modification of cysteine as fixed modification and oxidation of
methionine as variablemodification, 50 ppmmass tolerance for
MS and 0.3 Da for MS/MS fragment ions. Three spots were
picked in three different 2D gels (from three different healthy
subjects) and were identified in MS and/or MS/MS in order to
validate the protein identification in samples from different
subjects.
2.9. Databases of normal urinary proteins
The1.5 versionof theDatabaseofUrinary Proteins (DUP) (Salvetat
N et al. manuscript in preparation; http://www.sysdiag.cnrs.fr/
DUP/) collects 3080 proteins that have been reported in 19
publications to occur in human normal urine. The occurrence in
the DUP database of the proteins identified in this study was
checked. A publicly available database of proteins found in
various body fluids, including urine, was also used [28].3. Results3.1. Key assessments for urinary 2D-GE profiling studies
3.1.1. Collection and storage conditions
Maintaining protein integrity is a key issue in the collection
and storage of biological samples for clinical proteome
analysis, particularly for biomarker discovery. It is difficult,
however, to perfectly control after-collection conditions prior
to long-term freezer storage. In order to estimate the impact of
temperature after urine collection and before freezing at
−80 °C, urines were collected, kept at room temperature (RT)
for 1 h and then stored at +4 °C or at RT for another 7 h.
Afterwards, a qualitative and quantitative analysis by 2D-GE
was performed. For the qualitative analysis, all protein spots
in the gels were detected using the Progenesis Samespot®
software, the background was subtracted and, finally, the
presence or absence of a protein spot at a given position was
checked (the total number of protein spots per gel was also
ascertained). The number of protein spots in gels in which
urine samples stored at RT for 7 h were analysed, was
comparable to the number obtained when using urines stored
at +4 °C (ratio 1.08) (Fig. 1A). No quantitative changes as
measured by the mean intensity level (which reflects changes
in protein amount) were observed between urines stored at RT
for 7 h and urines stored at +4 °C. RT is a fuzzy parameter since
it may largely vary depending on the season and location. In
order to control this parameter and since there is no difference
observed between RT and 4 °C, we decided to fix it at 4 °C. An
evaluation of the effect of the storage temperature on the 2D
protein profile was also performed using fresh urine samples,
urines stored at −20 °C (with or without protease inhibitors)
and urines stored at −80 °C (Fig. 1A and B). This analysis was
carried out on four biological replicates (2 men and 2 women)collected twice at one month difference. Using the criteria
described above, no significant differences in the number of
protein spots and in mean intensity level were observed when
using fresh urines (574 protein spots) and samples stored at
−80 °C (536 protein spots) or at −20 °C+protease inhibitors (491
protein spots). Conversely, a significant qualitative change
was found between urine samples stored at −20 °C (386
protein spots) and fresh urines or samples stored at −80 °C/
−20 °C+protease inhibitors. The use of fresh urine seems to be
the best protocol for optimal protein integrity. However, this
option is not realistic for large scale proteomic analyses and
thereforewe decided to performour study using urine samples
stored immediately after collection (less than 2 h) at +4 °C and
then at −80 °C until use.
3.1.2. Total protein quantification and reduction and alkylation
of proteins before IEF
The modified Lowry method (RCDC protein kit assay) and the
Bradford method were compared for total urinary proteins
quantification. The coefficient of variation (CV) was calculated
for each assay and then for two different experimenters. The
RCDC kit showed less variation betweenmeasurements of the
same urine sample (experimenter 1: CV=0.06; experimenter 2:
CV=0.07) than the Bradford protein assay (experimenter 1:
CV=0.11; experimenter 2: CV=0.12).
To get high resolution 2D-GE patterns of urines, different
optimization steps were found necessary and in particular,
the analysis of different reducing (dithioerythritol, DTE; tris
(2-carboxyethyl) phosphine, TCEP) and alkylating (iodoace-
tamide, IAM; 4-vinylpyridine, VP) agents prior to the 1st
dimension run. The condition of reduction with DTE without
alkylation provided the best resolution for protein spots on
2D-GE gels (data not shown). Also, in order to optimise the
spot resolution in the basic zone of the gel, a paper soaked
with three different solutions (i.e., water, DTE or DeStreak
Rehydration Solution) was added to the electrode side of the
tank during IEF. Addition of a paper soaked with 50 mM DTE
seemed to favour spot resolution and also to increase slightly
the number of detectable spots in the basic area of gel (data
not shown). This optimised 2D protein separation protocol
was then applied in our study of the variability of healthy
human urinary proteome.
3.2. Post 2D-GE quality assessment
Proteins from urine samples from twenty apparently healthy
subjects (10menand10women)were separatedby2D-GE in two
different runs (10 gels per run). In order to compare the twenty
individual proteomes, it was important to assess the consisten-
cy of our dataset after 2D-GE separation. To this end, we used a
dispersion treeapproachwhichassesses theconsistencyofa set
of results from proteomic experiments [26]. The twenty 2D-GE
experiments were homogeneously dispersed (ideally, the twen-
ty branches of the tree would form a circle) (Fig. 2A) with only
one gel being slightly outside the circle. After careful examina-
tion, this gel did not present apparent defects. Its particular
behaviour was probably due to some particular intrinsic
properties of this sample and not to experimental problems
and thus the gel was retained for further analysis. The
homogeneity of the data was also confirmed by three other
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+ 4°C 604.5 ± 84.14 35.92  ± 4.54
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B
Fig. 1 – Number of spots in 2D-GE experiments using urine samples collected and stored at different temperatures. (A) Mean
number of spots in 2D-GE experiments for each temperature of sample collection and storage andmean spot intensity for each
tested condition. Two biological replicates were tested for post-collection conditions and four for storage conditions. Each
biological replicate was run in duplicate. (B) The distribution of the number of spots in 2D-GE experiments for different
temperatures of urine storage is shown in the box plot. The ends of the box are the 25th and 75th quantiles. The red and the
black line inside each box identify respectively the median and the mean of each group.*aSignificant difference in spot count
between fresh and −20 °C storage temperature; *bSignificant difference in spot count between −80 °C and −20 °C storage
temperature and *cSignificant difference in spot count between −20 °C and −20 °C+PI storage temperature. There was no
statistically significant difference in the mean number of spots and the mean intensity between all the other collection and
storage conditions.
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principal component analysis (PCA) (Fig. 2C) and the Pearson
correlation (Fig. 2D). Thehomogeneityofourdatasetwas further
corroborated by assessing the technical variability of 2D-GE and
the intra- and inter-individual changes in normal urinary
proteome on four different samples. The technical repeat
measurements gave a mean CV gel of 0.044 (CV spot=0.213)
and the variation of theproteomeof each of the four individuals
(intra-individual variability) was 0.122 (CV spot=0.305). The
inter-individual CV gel value was 0.115 (CV spot=0.448).
The influence of gender, age and protein concentration on
the variability of the urine proteomes was evaluated. There
was no significant difference between the data obtained with
female andmale urine samples as visualised by the dispersion
tree, Mahalanobis graph and PCA representation (Fig. 2). These
results confirm previous observations [12,20,21]. Moreover,
themean donor's age and total protein concentrationwere not
significantly different betweenmale and female samples (data
not shown).3.3. Variability of human normal urinary proteome
To estimate the variability of the normal urinary proteome, a
qualitative analysiswas thenperformed asdescribed above and
910 protein spots were aligned (mean number of spots per gel
was 498±107). This result is consistent with previous similar
studies, although the number is higher [13,17,21,23,29–31].
However, these 910 protein spots were not present in all gels
as shown by the virtual gel representation (Fig. 3B). The rough
similarity between the 2D profile of an individual sample
(Fig. 3A) and the virtual gel profile that represents all the
collected data (Fig. 3B) suggests a relative homogeneity in the
protein content of each urinary proteome. A large part of the
spots (35%) could be considered as conserved (322 protein spots
in light grey, i.e., occurring in 16 to 20 gels). The most and the
least conserved spots (protein spots occurring in 16 to 20 gels
and 1 to 5 gels, respectively) exhibited a broad spectrum ofMW,
pI and intensities, suggesting the absence of obvious bias
towards the characterization of conserved or variable proteins.
PC2
PC1
Women
Men
A B
C
D
Fig. 2 – Post 2D-GE quality assessment. (A) Dispersion tree of the twenty 2D-GE experiments. Spot intensities in each gel were
represented by an expression vector and the Euclidian distance between vectors was calculated. The resulting distance matrix
was used to perform a clustering of all the experiments and the data dispersion was analysed (the data from men's urine
samples are in blue and the data from women's urine samples in red). (B) Mahalanobis distance graph of the twenty 2D-GE
experiments. The Mahalanobis distance depends on the estimates of the mean, standard deviation and correlation of the data.
(C) Principal component analysis (PCA) of the twenty 2D-GE experiments. The first two principal components are used to map
each experiment into a 2D plot. (D) Pearson correlationmatrix of the twenty 2D-GE experiments. The colourmap of the Pearson
correlations coefficients shows the groups of samples that have similar correlations on a scale of correlation from red (+1) to
green (−1).
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distribution in the twenty gels (Fig. 4). About 13% (exactly,
13.07%) of the protein spots were present only in ten percent or
less of the samples and thus represented themost variable part
of the urinary proteome. On the other hand, 23% (23.6%) of the
protein spots were found in at least 90% of the samples and
16.15% of the spots (i.e., 147 protein spots) were present in all
gels.
To verify that spot conservation was not biased by the spot
intensity (i.e., the strongest spots being also the most
conserved because they are more easily detectable), spot
intensities were subjected to a hierarchical clustering analysis
(Fig. 5). Four main clusters of spots emerged and within each
cluster, the intensity of the protein spots was comparable (see
heat map in Fig. 5). The majority of the conserved spots (2central clusters) were characterised by a relatively moderate
intensity level (the green colour corresponds to low intensity
and the red colour to high intensity), while a smaller cluster
showed higher intensities (the red colour correspond to high
intensity level). Then the quantitative variations in intensity
of the 147 fully conserved spots were specifically evaluated by
calculating their mean intensity and dispersion (coefficient of
variation, CV). No correlation between CV and mean intensity
was found (R=0.44), indicating that, among the conserved
spots, the weakest spots were not associated with the greatest
variability (which could have been the case because of the
faint signal). Thus, if we consider that spots are representative
of proteins, our results indicate that a significant part (around
25%) of the normal urinary proteome is highly conserved and
that most of the conserved spots are of medium intensity.
pI 
Virtual gel
3 10
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W
 (k
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1
15
Occurrence in 1 to 5 gels
Occurrence in 6 to 10 gels
Occurrence in 11 to 15 gels
Occurrence in16 to 20 gels
2D gel 
A B
Fig. 3 – Experimental and virtual 2D-GE images. (A) Representative 2D-GE image of the urine proteome of one of the 20 normal
individuals. Precast IPG strips (pH 3-10NL) were rehydrated with 70 μg of protein sample and after the first dimension, proteins
were separated on 12% SDS-polyacrylamide gels. Gels were stained with silver nitrate. (B) Virtual gel representation of spot
variability within the 20 urinary samples computed with the Sili2Dgel software; the diameter of each spot is proportional to its
mean intensity and its colour is coded according to the number of time is present in the twenty 2D-GE experiments.
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conserved spots and four proteins corresponding to a
fraction of the highly variable spots (occurrence in 1 gel)
were then identified by excision from the protein spot,
trypsin digestion and peptide mass fingerprinting (Table 1,
Table S1). Eleven of themwere proteins present in the plasma
proteome, a finding which is in accordance with the known
blood filtration properties of the kidney. Some proteins were
found at MW positions in the 2D gel that matched their0
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Fig. 4 –Distribution of the number of spots found in the 20 2D-
GE. The presence of each individual spot in the twenty gels
was checked after alignment, then the background was
subtracted and, finally, the presence or absence of a spot at a
given position was checked. Occurrence of each protein spot
was counted in the twenty 2D-GE experiments. The numbers
above the double-headed arrows correspond to the percent-
age of spots found only in 10% (most variable proteome) and
in 90% (most conserved proteome) of the urinary samples.theoretical molecular weight (Epithelial Cadherin, Glutami-
nyl-Peptide Cyclotransferase, Phosphatidylethanolamine-
Binding Protein 4). Others were found at positions consistent
with spots belonging to proteolytically processed proteins
(e.g., Mannan-Binding Lectin Serine Protease 2, Serum
Albumin, AMBP, Basement Membrane-Specific Heparan
Sulfate Proteoglycan core protein, Trypsinogen 4). Finally,
many protein spots were at positions compatible with an
increased molecular weight due to post-translational mod-
ifications (e.g., Alpha-1β-Glycoprotein, Monocyte Differenti-
ation Antigen CD14, secreted and Transmembrane Protein 1,
Zinc-Alpha-2-Glycoprotein, Uromodulin, Alpha-1-antitryp-
sin). It was not possible, due to the limited number of
identified proteins, to determine whether the most con-
served spots and the highly variable spots corresponded
more frequently to full-length proteins rather than processed
proteins. In order to validate the identification of the most
conserved protein, three spots (including the one corre-
sponding to AMBP protein and its fragment) were picked
from three different 2D gels corresponding to three different
healthy subjects and analysed by MS or MS/MS. The protein
identification was confirmed for the three spots in the three
different samples. This confirmed the conservation of the
protein observed among the subjects.
Finally, our Database of Urinary Proteins and the Sys-
BodyFluid database [28] confirmed that most of the twenty
four identified proteins have been previously described
(Table 1) in more than 7 publications; only Phosphatidyleth-
anolamine-Binding Protein 4, Prostaglandin D2 synthase
21 kDa and Cell adhesion molecule 4 were reported only two,
three and five times, respectively. The Orphan short-chain
dehydrogenase/reductase and Trysinogen 4 were not previ-
ously described in the two urine databases studied.
Fig. 5 – Heatmap and hierarchical ascendant clustering of the
147 spots present in all 2D-GE. The intensity levels of the 147
spots present in all twenty 2D-GE experiments were visua-
lised by heatmap and hierarchical ascendant cluster analysis
(Pearson correlation with average linkage) using the JMP v8
software. Each column represents the data of one 2D-GE
experiment. Rows represent individual spots. Raw data were
mean-centred and the colour code is graduated from green
(low level of intensity) to red (high level of intensity).
Hierarchical clustering analysis was used to organise the
map and to group the spots according to nearest level of
intensity.
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The current major interest in the identification of clinical
urinary biomarkers for renal diseases and even for a larger
spectrum of pathologies requires i) standardisation of the
methods used for collection, storage and preparation of
samples and ii) estimation of the urine normal proteome
variability. Standardised protocols have recently been pro-
posed by the HKUPP (Human Kidney and Urine Proteome, EU)
and EuroKUP (European Kidney and Urinary Proteomics, EU
FP7) groups but some points have not been completely
evaluated: the addition of protease inhibitors is still under
investigation and in particular for the samples storage at
−20 °C. Moreover concerning the time of freezing, nothing was
indicated. We thus examined some of the parameters for
sample collection, storage and processing that may affect
proteomic analysis by 2D-GE approach. Several studies have
already evaluated these parameters using techniques like
SELDI [6,32,33], CE/MS [34], magnetic beads/MS [35] and 1D LC/
MS [2], that focus more on the urinary peptidome than on theproteome. Addition of protease inhibitors prior freezing was
also debated since this may interfere with the proteome
analysis [36,37]. Our study indicates that there are no
significant qualitative and quantitative changes in urine
samples stored at RT or +4 °C just after urine collection and
before freezing at −80 °C. These results confirm the stability of
urinary proteins for few hours before freezing [6,32]. The
comparison of the urinary 2D profile from samples freshly
used, stored at −20 °C with protease inhibitors or stored at
−80 °C showed no qualitative difference. Conversely, samples
stored at −20 °C without protease inhibitors presented a lower
protein spot count than samples stored in the other condi-
tions. It seems important to add protease inhibitors for long-
term storage at −20 °C for 2D profile study. By using a similar
approach, Havanapan and Thongboonkerd described no
quantitative and qualitative changes in urine samples stored
at −30 °C with or without protease inhibitors however,
samples were stored at −30 °C only 23 h [36]. Hence, on the
basis of our results and those described in the literature, the
immediate storage of urine samples at +4 °C (2 h maximum
after collection) until storage at −80 °C seems the best way for
long-term sample preservation for 2D-GE analysis of the urine
proteome. Moreover, this storage option is compatible with
clinical requirements [31,37].
The characterisation of the urinary proteome is the target of
many studies [38]. By omitting articles devoted to the identifi-
cation of urinary biomarkers, we found 19 recent publications
describing the proteomic content of normal human urine.
However, the repositories of more than 3000 unique urinary
proteins thatwe and others have established from the available
literature (DUP database and Sys-BodyFluid database [28]) do
not specify whether any of these proteins is unique to the
individual that provided the urine sample or shared by
everybody, even though the evaluation of the conservation/
variability of proteins in normal urines is important for the
discovery of urine biomarkers. To address the question of the
variability of the normal urinary proteome, we used the 2D-GE
method because it has high resolving power, it is semi-
quantitative and it allows the comparison of individual clinical
samples in a medium-throughput manner. In addition, differ-
ences in the isoelectric point ormolecularweight can be used to
differentiate post-translationally modified proteins [39]. The
analysis of the dispersion of results from the twenty 2D-GE
experiments (Fig. 2) confirmed the overall quality of the dataset,
thus allowing meaningful gel to gel comparisons of protein
spots.
Studies of proteins variability in normal urines are scarce
and their conclusions are conflicting [12,17,21,22]. Our findings
clearly indicate that the human urinary proteome is charac-
terised by a low variability as 13% of the spots represented the
variable components of the urine (i.e., present in only 10% of
samples), whereas 23.6% of the proteomewas highly conserved
(i.e., present in 90% or more of the samples). Khan and
colleagues studied the proteome of a single subject and found
important changes when assessing within-day and day-to-day
variations; these variations could increase the inter-individual
variationswe observed [17]. Our results and conclusions are not
in agreement with those of Oh et al. [12]. Thismay be explained
by the low number of samples they analysed (three vs. twenty),
differences in sample collection (1st vs. 2ndmorning urine) and
Table 1 – Identification of the protein spots.
Protein name Accession
number
(UniProt ID)
Origin P, plasma
protein
O, other origin
Ratio exp.
MW/
theoretical MW
Occurrences
in DUP a
Occurrences in
Sys-BodyFluid
database b
Alpha-1B-glycoprotein [precursor] P04217 P >1 10 5
AMBP protein [precursor] P02760 P <1 c 14 9
Antibody fragment P ND – –
Basement membrane-specific heparan
sulfate proteoglycan core protein
[precursor] [fragment]
P98160 O <1 11 6
Epithelial cadherin [precursor] P12830 O 1 7 4
Gelsolin [precursor] P06396 O <1 10 6
Glutaminyl-peptide cyclotransferase [precursor] Q16769 O 1 10 8
Kininogen-1 [precursor] P01042 P <1 13 8
Lysosomal acid phosphatase [precursor] P11117 O >1 10 6
Lysosomal alpha-glucosidase [precursor] P10253 O 1 or <1d 9 3
Mannan-binding lectin serine protease 2 [precursor] O00187 P <1 12 6
Monocyte differentiation antigen CD14 [precursor] P08571 O >1 10 6
Phosphatidylethanolamine-binding protein 4
[precursor]
Q96S96 O 1 2 1
Prostaglandin D2 synthase 21 kDa (brain) [fragment] Q5SQ09 O >1 3 2
Prostate specific antigen precursor P07288 P >1 8 6
Secreted and transmembrane protein 1 [precursor] Q8WVN6 O >1 10 6
Serotransferrin [precursor] P02787 P >1 c 15 9
Serum albumin precursor P02768 P <1 or >1e 10 9
Uromodulin [precursor] P07911 O >1 14 8
Zinc-alpha-2-glycoprotein [precursor] P25311 P >1 12 6
Orphan short-chain dehydrogenase/reductase f Q8NEX9 O <1 0 0
Trypsinogen 4 f A8CED1 P >1 c 0 0
Cell adhesion molecule 4 f Q8NFZ8 O >1 5 3
Alpha-1-antitrypsin f P01009 P >1 15 9
a The Database of Urinary Proteins, release 1.5, lists 3080 non-redundant entries of proteins that have been found in 19 articles on urinary
proteomics.
b The Sys-BodyFluid Database lists 1941 (partially redundant) entries from 9 articles on urinary proteomics.
c Two different spots yielded the same protein assignment.
d Two different spots yielded the same protein assignment, one with an apparent MW of 106 kDa and the other of 69.6 kDa, compared to the
theoretical MW of 105.338 kDa.
e Two different spots yielded the same protein assignment, one with an apparent MW of 53.9 kDa and the other of 78 kDa, compared to the
theoretical MW of 69.367 kDa.
f Proteins identified from highly variable spots (occurrence in 1 gel).
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larly, the study by Thongboonkerd and colleagues, although
performedona larger sample (8 individuals)wasonlybasedona
small number of aligned spots (115−246) and probably missed
some of the medium/low intensity spots [21]. This could have
greatly biased the authors' conclusions, sincewe found that the
conservedproteomecomprisesmostly low tomedium intensity
spots. Adachi et al. showed by LC-MS that the urinary proteome
of a single person comprises amajor set (61.9%) of proteins that
is also found in a pool of 9 urines [18]. By a similar approach,
Nagaraj andManndescribed a common and abundant set (72%)
of proteins in seven normal individuals [20]. These recent
reports and our findings contribute to the view that, in urine, a
minor variable protein set coexists with a major conserved
proteinset.However,we foundasmallerpercentage (about24%)
of conserved proteins in comparison to the studies inwhich LC-
MS was used (more than 60%). Indeed, when using 2D-GE
methods for protein separation, the same protein could be
represented in different spots with different molecular weight
and isoelectricpoint.Conversely, LC-MS isa global analysisof allproteins present in samples and it does not distinguish among
the possible different forms (modified, fragmented) of a protein.
By looking at the intensity distribution and spot conserva-
tion, the highly conserved spots were in average more intense
than the poorly conserved (supplementary data Fig. S1).
However, a large overlap of intensities from highly conserved,
medium conserved and highly variable spots exits (Fig. S1).
Interestingly, the poorly and moderately conserved spots show
a rather similar distribution (although the intensity seems to
have little influence). Although the intensity might influence
the conservation assessment, it is certainly not the main cause
of conservation/variability. The consequence is probably an
over estimationof variableproteome ina 2Dgel experiment and
an underestimation of the conserved proteome.
The protein identification study indicates that few spots,
occurring at different positions in the gels, were assigned to the
same protein (Lysosomal Acid Glucosidase, Serum Albumin,
antibody fragments, AMBP, Serotransferrin, Trysinogen4). This is
consistent with the coexistence in urine of full-length and
degraded forms of a given protein [40]. Nine of the identified
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proposed ratio of 30%ofurinaryproteins originating fromplasma
filtrationby the kidney glomeruli [9,41]. However, the finding that
several of these proteins have highmolecular weights, questions
the size criteria that are used as ameasure of the functionality of
the glomerular filtration barrier [42,43]. The analysis of the
occurrence of the 24 proteins in the literature was facilitated by
the availability of the DUP and Sys-BodyFluid databases. Most of
theproteinswerementioned in several publications (7 to 15)with
the exception of Phosphatidylethanolamine-binding protein 4,
Prostaglandin D2 synthase 21 kDa, Cell adhesion molecule 4,
Orphan short-chain dehydrogenase/reductase and Trysinogen 4.
An unexpected findingwas the identification of Prostate Specific
Antigen (PSA) both inmale and femaleurine samples. It is known
that PSA is a circulating molecule in small amount in healthy
men [44]. PSA was also previously observed in 38% of female
urines [45] due to production by the periurethral glands [46].
Another study showed that 80% of healthy women's urines
contain detectable amount of PSA, a proportion that increases up
to92% inwomen takingoral contraceptives [47].As it is likely that
most of the women who participated in our study were under
hormonal treatment, this could explain our observation.
Our attempt to characterise quantitative variations in the
conserved part of the urinary proteins shows that most of the
conservedspotsarecharacterisedbya largespectrumof intensity
(from weak to high). They possibly correspond to minor plasma
proteins filtered fromthe glomeruli, to small amounts of proteins
released from renal epithelial cells, or to protein fragments
released through enzymatic cleavage by tubular enzymes.
In conclusion, a “public”urinary proteomewhich is common
to healthy individuals seems to coexist with a “private” urinary
proteome, which ismore specific to each individual. Our results
show that a significant part of the normal urinary proteome
seems to be “public” i.e., shared among individuals. This crucial
information should be kept in mind when looking at urinary
biomarkers of diseases. Indeed, if a biomarker belongs to the
“public” part of the urinary proteome, only its quantitative
variations will be of use in clinical diagnostic. Conversely, if a
putative biomarker belongs to the “private” proteome, the
detection of its absence/presence is more likely to be of
diagnostic value. It thus appears necessary now to determine
which proteins are common to all individuals and which are
present only in some individuals. At the same time, important
efforts need to be realised to render proteomic methods more
susceptible to yield quantitative information [48]. In the future
standardised exhaustive maps of the normal urinary proteome
from samples that have been collected/stored following differ-
ent procedures (with the identification of all protein spots) will
be helpful to further investigate the human urine variability.
Supplementary materials related to this article can be
found online at doi:10.1016/j.jprot.2011.06.031.Acknowledgements
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